21 November: The FDA has issued EUA for REGN-COV2 to be used for mild to moderately sick COVID-19 patients, of age 12 years and older, who are at high risk of progressing to severe disease. It has not been authorised for patients who are hospitalised due to COVID-19 or those who require oxygen therapy.
2 November: Regeneron has announced they will stop enrolling very ill patients in the clinical trial of their antibody treatment. Patients on high levels of supplemental oxygen,and intubated patients, may face more risks than benefits from the therapy, according to an independent data monitoring committee. Hospitalised patients who are on low levels of oxygen, or none, will still be enrolled. Because the medication is given intravenously, it might be difficult to give to people who are not hospitalised.
28 October: In another press release, Regeneron has stated that data from an additional 524 patients in their ongoing Phase 2/3 trial of REGN-CoV2 shows further positive results. "REGN-COV2 significantly reduced viral load and patient medical visits (hospitalizations, emergency room, urgent care visits and/or physician office/telemedicine visits)."
The company applied for FDA Emergency Use Authorisation (EUA) earlier in the month. These data have also been shared with the FDA.
Several trials of REGN-CoV2 continue in the United States and the United Kingdom, as treatment for both non-hospitalised and hospitalised patients, as well as a preventative for household contacts of COVID-19 cases.
3 October: The pharmaceutical company Regeneron announced early results of clinical trials on their antibody treatment REGN-COV2. "The REGN-COV2 is a combination of two monoclonal antibodies (REGN10933 and REGN10987) and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19." Analysis so far shows " it reduced viral load and the time to alleviate symptoms in non-hospitalized patients with COVID-19. REGN-COV2 also showed positive trends in reducing medical visits." "The greatest treatment benefit was in patients who had not mounted their own effective immune response, suggesting that REGN-COV2 could provide a therapeutic substitute for the naturally-occurring immune response". The trials are ongoing.